Evidence mapPaperPMID 33287464Full record

ReviewInternational journal of molecular sciences2020

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.

Ellen Frejborg, Tuula Salo, Abdelhakim Salem

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Therapeutic targeting of COX-2 in head and neck cancer: Mechanistic and clinical perspectives.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  3. CRISPR/Cas9-mediated Knockout ofCancer genomics & proteomics · 2025
    Article
  4. Frontiers in nutrition · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ellen FrejborgDepartment of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, 00014 Helsinki, Finland.
Tuula SaloDepartment of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, 00014 Helsinki, Finland.
Abdelhakim SalemDepartment of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0002-9455-3823
University of Helsinki · FI

Funding

Cancer Society of Finland NAHelsinki University Central Hospital Research Funds NAJane ja Aatos Erkon Säätiö NAMinerva Foundation Institute for Medical Research NASigrid Juséliuksen Säätiö NASyöpäjärjestöt NA
6 · The paper itself

Abstract

The cyclooxygenase-2 (COX-2) is a potent enzyme that converts arachidonic acid to prostaglandins (PG), including PGE2, a key mediator of inflammation and angiogenesis. Importantly, COX-2 is activated in response to inflammatory stimuli, where it is also believed to promote the development and progression of head and neck cancers (HNC). COX-2 can mediate its protumorigenic effect through various mechanisms, such as inducing cell proliferation, inhibition of apoptosis, and suppressing the host's immune response. Furthermore, COX-2 can induce the production of vascular endothelial growth factors, hence, promoting angiogenesis. Indeed, the ability of COX-2 inhibitors to selectively restrict the proliferation of tumor cells and mediating apoptosis provides promising therapeutic targets for cancer patients. Thus, in this comprehensive review, we summarized the reported differential expression patterns of COX-2 in different stages of head and neck carcinogenesis-from potentially premalignant lesions to invasive carcinomas. Furthermore, we examined the available meta-analysis evidence for COX-2 role in the carcinogenesis of HNC. Finally, further understanding of the biological processes of COX-2 and its role in orchestrating cell proliferation, apoptosis, and angiogenesis may give therapeutically beneficial insight to develop the management plan of HNC patients and improve their clinical outcomes.

Indexed as

AnimalsBiomarkersCell Transformation, NeoplasticCyclooxygenase 2Disease ManagementGene Expression RegulationGenetic Predisposition to DiseaseHead and Neck NeoplasmsHumansInflammation MediatorsPolymorphism, GeneticPrognosisRisk AssessmentTumor MicroenvironmentBiomarkersCyclooxygenase 2Inflammation Mediatorscarcinogenesiscyclooxygenase-2head and neck cancershead and neck squamous cell carcinomainflammationpotentially premalignant lesionsprostaglandins

Identifiers

PMID33287464
PMCPMC7731111
OpenAlexW3109864710

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.